COVID-19-related adaptations to the implementation and evaluation of a clinic-based intervention designed to improve opioid safety.

academic detailing all-payer claims database opioid safety practice facilitation prescription drug monitoring programs

Journal

Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187

Informations de publication

Date de publication:
2021
Historique:
received: 13 07 2021
accepted: 24 09 2021
entrez: 31 12 2021
pubmed: 1 1 2022
medline: 1 1 2022
Statut: epublish

Résumé

The United States faces an opioid crisis with an unprecedented and increasing death rate from opioid overdose. Successfully reducing the rates of opioid use disorder (OUD) and overdose will require the engagement of frontline clinicians to prescribe opioids more safely and to build their capacity to treat patients with OUD using evidence-based approaches. The COVID-19 pandemic has created significant challenges for patients, clinicians and health systems and has been associated with increasing risks of overdoses and deaths. Herein, we review a multidisciplinary project designed to implement and evaluate clinic-based interventions in Oregon, USA, to improve pain management, opioid prescribing and treatment of OUD. The intervention, called Improving PaIn aNd OPiOId MaNagemenT in Primary Care (PINPOINT), combines practice facilitation, academic detailing and education through the Oregon ECHO Network. Implementation of PINPOINT has occurred across the Oregon Rural Practice-based Research Network and has involved 49 clinic sites to date. To evaluate the impact of the intervention, the research team created the Provider Results of Opioid Management and Prescribing Training (PROMPT), a dataset that links information from the state prescription drug monitoring program, all-payer claims database, emergency medical services, vital records and substance use disorder treatment system. The PROMPT dataset will allow evaluation of the impact of the intervention at both the clinician and clinic levels. Due to the constraints of the COVID-19 pandemic, elements of both implementation and evaluation required significant adaptations to continue to meet the original project goals.

Identifiants

pubmed: 34970321
doi: 10.7573/dic.2021-7-5
pii: dic-2021-7-5
pmc: PMC8687093
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Informations de copyright

Copyright © 2021 Morgan AR, Hendricks MA, El Ibrahimi S, Hallvik SE, Hatch B, Dickinson C, Wright D, Fischer MA.

Déclaration de conflit d'intérêts

Disclosure and potential conflicts of interest: MAF serves as a clinical consultant for Alosa Health, an educational non-profit that provides academic detailing services, and directs the National Resource Center for Academic Detailing, a program within the Division of Pharmacoepidemiology and Pharmacoeconomics. NaRCAD is funded by grants from AHRQ (R18HS026177 and R13HS026829) and contracts from the CDC and NACCHO. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/10/dic.2021-7-5-COI.pdf

Références

JAMA. 2014 Apr 9;311(14):1393-4
pubmed: 24577059
MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
Implement Sci Commun. 2020 Feb 26;1:16
pubmed: 32885178
Prehosp Emerg Care. 2021 Nov-Dec;25(6):768-776
pubmed: 33147081
J Clin Epidemiol. 2011 Sep;64(9):936-48
pubmed: 21411284
JAMA Intern Med. 2019 Apr 1;179(4):574-576
pubmed: 30742206
Ann Emerg Med. 2004 Apr;43(4):494-503
pubmed: 15039693
JAMA. 2020 Oct 27;324(16):1615-1617
pubmed: 32945831
JAMA Intern Med. 2019 Apr 1;179(4):469-476
pubmed: 30742196
Ann Emerg Med. 2012 Aug;60(2):199-206
pubmed: 22032803
J Gen Intern Med. 2021 Jun;36(6):1503-1513
pubmed: 33852140
JAMA. 1993 Mar 24-31;269(12):1537-9
pubmed: 8445817
Ann Fam Med. 2019 Jul;17(4):319-325
pubmed: 31285209
Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):927-933
pubmed: 33913205
JAMA. 2017 May 16;317(19):2013-2015
pubmed: 28510669
Annu Rev Public Health. 2015 Mar 18;36:559-74
pubmed: 25581144
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Emerg Med J. 2014 Oct;31(e1):e2-8
pubmed: 24136118
JAMA Intern Med. 2019 Apr 1;179(4):476-478
pubmed: 30742214
Paediatr Respir Rev. 2020 Sep;35:38-42
pubmed: 32653468
Ann Intern Med. 2011 Sep 6;155(5):325-8
pubmed: 21893626
J Pain. 2011 Dec;12(12):1199-208
pubmed: 21945594
Ann Fam Med. 2012 Jan-Feb;10(1):63-74
pubmed: 22230833
Am J Public Health. 2009 Feb;99(2):221-7
pubmed: 18799767
JAMA Netw Open. 2019 Jan 4;2(1):e186007
pubmed: 30657529
Fam Med. 2017 Jul;49(7):537-543
pubmed: 28724151
CMAJ. 2019 Jul 22;191(29):E822-E823
pubmed: 31332055

Auteurs

Anna R Morgan (AR)

National Resource Center for Academic Detailing, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.

Michelle A Hendricks (MA)

Comagine Health, Portland, OR, USA.

Sanae El Ibrahimi (S)

Comagine Health, Portland, OR, USA.
School of Public Health, University of Nevada, Las Vegas, Las Vegas, NV, USA.

Sara E Hallvik (SE)

Comagine Health, Portland, OR, USA.

Brigit Hatch (B)

Oregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.

Caitlin Dickinson (C)

Oregon Rural Practice-based Research Network, Oregon Health & Science University, Portland, OR, USA.

Dagan Wright (D)

Injury and Violence Prevention Program, Public Health Division, Oregon Health Authority, Portland, OR, USA.

Michael A Fischer (MA)

National Resource Center for Academic Detailing, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.

Classifications MeSH